Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Background: Dementia and depression are increasingly common worldwide, and their effective control could ease the burden on economies, public health systems, and support networks. Vortioxetine is a new antidepressant with multipharmacologic actions that elevate the concentration of serotonin and modulate multiple neurotransmitter receptors in the brain. We conducted a meta-analysis to explore whether the cognitive function of patients with major depressive disorder (MDD) treated with vortioxetine would improve. Methods: We systematically reviewed randomized controlled trials (RCTs) in the PubMed, Embase, and Cochrane databases to assess the treatment effects of vortioxetine on the cognitive function of patients with MDD. The outcome measures included the Digit Symbol Substitution Test (DSST), Perceived Deficits Questionnaire (PDQ), and Montgomery-Åsberg Depression Rating Scale (MADRS) scores. Pooled results were calculated using a fixed-effects or random-effects model according to the heterogeneity of the included trials. Results: Six RCTs with a total of 1782 patients were included in the meta-analysis, which demonstrated that vortioxetine improved DSST, PDQ, and MADRS scores in patients with MDD. The results were consistent at the 10- and 20-mg doses. In the 20-mg group, the decrease in MADRS scores was more significant than that in the placebo group. Conclusions: Both the 10- and 20-mg doses of vortioxetine can significantly increase DSST scores and decrease PDQ and MADRS scores in patients with MDD and cognitive dysfunction, but further studies with longer follow-up periods to assess mental function are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 7×
“Three RCTs reported data on MADRS scores (McIntyre et al., 2014; Mahableshwarkar et al., 2015; Inoue et al., 2020).”
BackgroundInfluentialRetractedDiagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We used a random-effects model (DerSimonian and Laird, 1986) to pool the estimates according to the presence or absence of heterogeneity.”
MethodCochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395 · cited 1×
“Furthermore, immune dysregulation, such as increased proinflammatory cytokines interleukin-1b, tumor necrosis factor-ɑ, and interferons, were also noticed in depressed human and animal models (Dantzer et al., 2008; Wohleb et al., 2016).”
BackgroundCumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218
McGuinness, L. A., & Higgins, J. P. T. (2021) · Research Synthesis Methods · doi:10.1002/jrsm.1411 · Cited by 5,579 · cited 6×
“Three RCTs reported data on MADRS scores (McIntyre et al., 2014; Mahableshwarkar et al., 2015; Inoue et al., 2020).”
BackgroundInfluentialDiniz, B. S., Butters, M. A., Albert, S. M., Dew, M. A., & Reynolds, C. F. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.118307 · Cited by 1,290 · cited 1×
“Diniz et al. (2013) found a link between depression in older adults (adults aged above 65-year-old) and the risk of dementia, including both Alzheimer disease and vascular dementia.”
Background
Research works printed but not linked: 1
- McQuaid JR, Lin EH, Barber JP, Breland-Noble AM, Cuijpers P, Greenberg LS, Jones VY, Kessler MM, Mufson LH, Nezu AM, Reynolds CF, III, Scogin F, Jr. (2019) APA Guideline for the Treatment of Depression; chap: discussion of clinical recommendations, pp. 39– 40.
Cited by
Depression in Alzheimer’s Disease: Epidemiology, Mechanisms, and Treatment
Huang, Y.-Y., Gan, Y.-H., Yang, L., Cheng, W., & Yu, J.-T. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.10.008 · Cited by 164
Rhee, T. G., Shim, S. R., Manning, K. J., Tennen, H. A., Kaster, T. S., d’Andrea, G., Forester, B. P., Nierenberg, A. A., McIntyre, R. S., & Steffens, D. C. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000535665 · Cited by 102
“While one meta-analysis suggested that antidepressants, particularly SSRIs, may improve multiple domains of cognition in adults with MDD [68], some studies [69, 70] suggested differential effects of antidepressants on cognition, requiring further research.”
Christensen, M. C., Schmidt, S. N., & Grande, I. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.06.024 · Cited by 39
Steardo, L., D’Angelo, M., Monaco, F., Stefano, V. D., & Steardo, L. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106030 · Cited by 46
Nicola, M. D., Pepe, M., Montanari, S., Spera, M. C., Panaccione, I., Simonetti, A., & Sani, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.02.006 · Cited by 27
Li, Z., Liu, S., Wu, Q., Li, J., Yang, Q., Wang, X., Peng, P., Wang, Q., Liu, Y., Li, M., et al. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad018 · Cited by 30
“A meta-analysis of RCTs confirmed that both 10 and 20 mg of vortioxetine significantly increased Digit Symbol Substitution test scores and decreased Perceived Deficits Questionnaire-Depression scores in patients with MDD and cognitive dysfunction (Huang et al., 2022).”
BackgroundMethodResultInfluentialNelson, J. C., Gandelman, J. A., & Mackin, R. S. (2024) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2024.08.015 · Cited by 20
Cuomo, A., Aguglia, A., Berardis, D. D., Ventriglio, A., Gesi, C., & Fagiolini, A. M. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00505-1 · Cited by 13
Wang, N., Wang, L., Wang, J., Chen, R., Shi, M., Liu, H., & Xu, X. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07250-5 · Cited by 14
Martiadis, V., Pessina, E., Cattaneo, C. I., Martini, A., Raffone, F., Prodi, T., Olivola, M., Berardis, D. D., Benatti, B., & Dell’Osso, B. M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1617345 · Cited by 12
Use of vortioxetine in different neurological fields: a systematic review and future perspectives
Verrienti, G., Colonna, I., & Raccagni, C. (2025) · Neurological Sciences · doi:10.1007/s10072-025-07987-1 · Cited by 9
Neurobiological and therapeutic landmarks of depression associated with Alzheimer’s disease dementia
Untu, I., Davidson, M., Stanciu, G. D., Rabinowitz, J., Dobrin, R., Vieru, D. S., & Tamba, B.-I. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1584607 · Cited by 17
Rose, D., Lyketsos, C. G., Rosenberg, P. B., & Nowrangi, M. A. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00788 · Cited by 17
“Vortioxetine, another multimodal antidepressant with serotonin receptor modulation properties, has demonstrated improvements in both cognitive function and mood in patients with major depressive disorder [98].”
Berardelli, I., Rogante, E., Formica, F., Iannazzo, R., mammoliti, A. V., Riccioni, R., Veizi, S., McIntyre, R. S., & Pompili, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811241309612 · Cited by 8
“…FDAapproved treatment specifically for cognitive dysfunction in MDD (Lundbeck, 2018), and growing evidence, including the present study, supported its significant clinical benefits on cognitive function (Baune et al., 2018; Huang et al., 2022; Subramaniapillai et al., 2019; Zhang et al., 2022).”
The dose-response relationship of vortioxetine on major depressive disorder: an umbrella review
Wang, P., Wang, W., Liu, Y., Li, W., Hu, J., Su, Y., Li, J., Li, N., & Si, T. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116118 · Cited by 6
García‐Alberca, J. M., de la Guía, P., Gris, E., Mendoza, S., de la Rica, M. L., Barbancho, M. Á., Lara, J. P., & Blanco‐Reina, E. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090918 · Cited by 7
Wang, G., Si, T., Rieckmann, A., Ma, J., & Christensen, M. C. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s460408 · Cited by 5
“21 Improvements in multiple domains of cognitive functioning have been reported during treatment with vortioxetine, including global cognition, executive functioning, processing speed, attention, and working memory.”
BackgroundVuorio, A. F., Suhonen-Malm, A.-S., Budowle, B., & Bor, R. J. (2024) · Aviation Psychology and Applied Human Factors · doi:10.1027/2192-0923/a000271 · Cited by 5
Alessi, M. R., Barroso, D. C., Barbosa, E. C., Sehgal, K., Vieira, G. H., Miozzo, I. A., Freitas, V. T. H., Larcipretti, A. L. L., Balogun, M., Miyashiro, L., et al. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104409 · Cited by 5
Eliaçık, S., & Kaya, A. E. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1398417 · Cited by 4
Liu, H., Zhu, T., Zhang, L., Li, F., Zheng, M., Chen, B., Zhu, H., Ren, J., Lu, X., & Huang, C. (2024) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000774 · Cited by 3
“…most studies are focusing on the development of drugs to ameliorate the symptoms of the disease that have already developed, and fortunately, various types of drugs targeting monoamine dysfunction are successfully used in the clinic to treat depression (Huang et al ., 2022b; Kishi et al ., 2023).”
BackgroundPharmacological treatment of major depression
Vázquez, G. H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33580-8.00018-0 · Cited by 3
Choi, K., Lee, T., Lee, S., & Im, C. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf042 · Cited by 2
“Notably, a meta-analysis reported that vortioxetine improves cognitive impairment, 57 supporting our f indings.”
Alcalá, J. Á., Dorado, V. O., Herrera, G. D. P. A., Chamón, S. L., & Molinera, V. G. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1568777 · Cited by 2
Cuomo, A., Barillà, G., Cattolico, M., Pardossi, S., Mariantoni, E., Koukouna, D., Carmellini, P., & Fagiolini, A. M. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2333394 · Cited by 3
“Beyond isolated short-term RCTs, the cognitive-improving properties of vortioxetine have been validated in three meta-analyses [7,58,59] and one open-label study [60] in which cognitive function was reported as the primary outcome variable.”
BackgroundReznik, A. M., Syunyakov, T., Mudrak, A. V., Zakharov, N. B., Popova, Z. B., Khoroshilova, A. N., Ig, K., Sayfulina, A. M., Eliseenko, A. M., Matvievskaya, T. K., et al. (2023) · Consortium Psychiatricum · doi:10.17816/cp3728 · Cited by 2
Mishra, S., Mudgal, V., Bagul, K. R., Jain, P., & Pal, V. (2025) · Cureus · doi:10.7759/cureus.79365 · Cited by 1
“…regarding cognition and depressive symptoms, noting numerical improvements across the Digit Symbol Substitution Test (DSST), Perceived Deficits Questionnaire (PDQ), and Montgomery-Åsberg Depression Rating Scale (MADRS) scores, although these results were not statistically significant [16].”
Mental health update – update on depression with a focus on vortioxetine
Jordaan, B. (2024) · SA pharmaceutical journal. · doi:10.36303/sapj.1141 · Cited by 1
Gil‐Peinado, M., Pardo, J., García-Zamora, M., Meseguer, G. M. A., Sendra‐Lillo, J., & Moreno, L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1624989 · Cited by 2
“Vortioxetine (66), a multimodal antidepressant with potential procognitive effects, could enhance the safety of antidepressant treatment (67), quality of life and health outcomes (68) related to depression.”
Oughli, H. A., Ainsworth, N. J., Butters, M. A., Brown, P. J., Gebara, M. A., Gettinger, T. R., Karp, J. F., Lavretsky, H., Lenard, E. M., Miller, J. P., et al. (2025) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2025.100767 · Cited by 2
Dølven, S., Moroń, M., Eriksen, I., Toft, J. E. G., & Semkovska, M. (2025) · Neuropsychology Review · doi:10.1007/s11065-025-09686-2 · Cited by 2
Challenges and perspectives in dementia diagnosis
Lochman, I., Novobilský, R., & Kušnierová, P. (2025) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2025.007
Vortioxetine effectiveness in the treated major depressive disorder patients in Saudi Arabia
Garatli, A., Saad, S., Alowesei, R., Xavier, F., Zeina, M., Lofty, W., Khalid, M., Alharthi, N., Talaat, T., & Asiri, S. A. (2025) · Annals of General Psychiatry · doi:10.1186/s12991-025-00585-7
Grande, I., Schmidt, S. N., Reines, E. H., & Christensen, M. C. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s549106
Cognitive Effects of Esketamine in Treatment-Resistant Depression: A Systematic Review
Guglielmo, R., Facchinetti, E. L., Cioci, D., Olivola, M., da Silva, B. P., Mazzocchi, A., Dell’Osso, B. M., Amore, M., & Serafini, G. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002165 · Cited by 2
“13,14 Esketamine, the S-enantiomer of ketamine and an NMDA receptor antagonist, has emerged in recent years as an important therapeutic option for TRD. 15 The intranasal formulation (esketamine nasal spray) is approved by major regulatory agencies, including the US Food and Drug Administration and…”
Ramachandran, T., Ng, C. G., Wong, J. J. I., & Adlan, A. S. A. (2026) · Pharmacoepidemiology · doi:10.3390/pharma5020014
“Numerous randomized controlled trials and meta-analyses of vortioxetine have shown positive impacts on functional outcomes and both subjective and objective cognitive measures [14–16].”
Thakur, A., Jain, P., Sharma, M. K., Chauhan, N. S., Khatoon, N., Sahu, D., Ajazuddin, & Tamrakar, S. (2026) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-026-00331-7
“Vortioxetine, which has multimodal serotonergic activity, has been shown to have positive effects on executive functioning processing speed and cognitive flexibility over an 8-week clinical trial in patients with major depressive disorder [33].”
Xu, H., Fan, H., Ding, E.-H., Hou, P., Jiang, B., & Zhu, W.-B. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1837566
“…in Pharmacology frontiersin.org across both behavioral and molecular endpoints mirrors clinical observations where vortioxetine exhibits dose-dependent therapeutic effects, particularly on cognitive symptoms often refractory to SSRIs (Bennabi et al., 2019; Huang et al., 2022; Sanchez et al., 2015).”
Yang, L., Zhang, Q., Zhang, Y., Yao, K., Chen, X., Tian, H., & Zhuo, C. (2026) · ALPHA PSYCHIATRY · doi:10.31083/ap56752
Магомедова, Т. С., & Umakhanova, Z. R. (2026) · The Clinician · doi:10.17650/1818-8338-2026-20-1-k769
Baldini, V., Martinelli, G., Ronchi, D. D., & Macchiarulo, M. (2026) · Aging & Mental Health · doi:10.1080/13607863.2026.2730471
Metadata
- Authors
- Huang, I.-C., Chang, T.-S., Chen, C., & Sung, J.-Y.
- Affiliations
- Wan Fang Hospital (TW)
- Corresponding author
- Sung, Jia-Ying
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-08-19
- Volume
- 25
- Issue
- 12
- Pages
- 969-978
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC9743961
- OpenAlex
- W4293790530
- Cited by
- 41
- References
- 53
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 11 · 2023: 6
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Wan Fang Hospital, Taipei Medical University (110TMU-WFH-13)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- vortioxetine, major depressive disorder, cognitive impairment, cognitive function, antidepressants, serotonin, Digit Symbol Substitution Test, Montgomery-Asberg Depression Rating Scale, dose comparison
- MeSH terms
- Vortioxetine, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Humans, Piperazines, Sulfides, Randomized Controlled Trials as Topic, Treatment Outcome, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.